title: Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients.
abstract: To assess the efficacy of golimumab (GLM) in refractory uveitis associated to spondyloarthritis (SpA).
  
  
  
  Multicenter study of SpA-related uveitis refractory to at least 1 immunosuppressive drug. The main outcome variables were degree of anterior and posterior chamber inflammation, visual acuity, and macular thickness.
  
  
  
  A total of 15 patients (13 men/2 women; 18 affected eyes; mean age 39 ± 6 years) were evaluated. The underlying SpA subtypes were ankylosing spondylitis (n = 8), psoriatic arthritis (n = 6) and non-radiographic axial SpA (n = 1). The ocular involvement patterns were recurrent anterior uveitis in 8 patients and chronic anterior uveitis in 7. Before GLM they have received methotrexate (n = 13), sulfasalazine (n = 6), pulses of methylprednisolone (n = 4), azathioprine (n = 3), leflunomide (n = 2), and cyclosporine (n = 1). Overall, 10 of them had also been treated with TNF-α blockers; etanercept (n = 7), adalimumab (n = 7), infliximab (n = 6), and certolizumab (n = 1). GLM was given at the standard dose (50mg/sc/monthly) as monotherapy (n = 7) or in combination with conventional immunosuppressive drugs (n = 8), mainly methotrexate. Most patients had rapid and progressive improvement of intraocular inflammation parameters. The median number of cells in the anterior chamber at 2 years [0 (0-0)] was significantly reduced compared to baseline findings [1 (0-3); p = 0.04]. The mean best corrected visual acuity value also improved (0.84 ± 0.3 at 2 years versus 0.62 ± 0.3 at baseline; p = 0.03). Only minor side effects were observed after a mean follow-up of 23 ± 7 months.
  
  
  
  Our results indicate that GLM may be a useful therapeutic option in refractory SpA-related uveitis.
authors.affiliation: Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avda. Valdecilla s/n, ES-39008 Santander, Spain.
authors.forename: Vanesa
authors.initials: V
authors.lastname: Calvo-Río
authors.affiliation: Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avda. Valdecilla s/n, ES-39008 Santander, Spain.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Blanco
authors.affiliation: Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avda. Valdecilla s/n, ES-39008 Santander, Spain.
authors.forename: Montserrat
authors.initials: M
authors.lastname: Santos-Gómez
authors.affiliation: Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
authors.forename: Esteban
authors.initials: E
authors.lastname: Rubio-Romero
authors.affiliation: Division of Ophthalmology, Hospital de León, León, Spain.
authors.forename: Miguel
authors.initials: M
authors.lastname: Cordero-Coma
authors.affiliation: Division of Rheumatology, Hospital de Mérida, Badajoz, Spain.
authors.forename: Adela
authors.initials: A
authors.lastname: Gallego-Flores
authors.affiliation: Division of Rheumatology, Hospital de Mérida, Badajoz, Spain.
authors.forename: Raúl
authors.initials: R
authors.lastname: Veroz
authors.affiliation: Division of Rheumatology, Hospital Basurto, Bilbao, Spain.
authors.forename: Ignacio
authors.initials: I
authors.lastname: Torre
authors.affiliation: Division of Rheumatology, Hospital Doctor Negrín Canarias, Las Palmas, Spain.
authors.forename: Félix Francisco
authors.initials: FF
authors.lastname: Hernández
authors.affiliation: Division of Rheumatology, HUCA La Coruña, Asturias, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Atanes
authors.affiliation: Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avda. Valdecilla s/n, ES-39008 Santander, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Loricera
authors.affiliation: Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avda. Valdecilla s/n, ES-39008 Santander, Spain.
authors.forename: M C
authors.initials: MC
authors.lastname: González-Vela
authors.affiliation: Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avda. Valdecilla s/n, ES-39008 Santander, Spain.
authors.forename: Natalia
authors.initials: N
authors.lastname: Palmou
authors.affiliation: Department of Internal Medicine, Hospital Marqués de Valdecilla, University of Cantabria-IDIVAL, Red Temática de Investigación Cooperativa en Envejecimiento y Fragilidad (RETICEF), Santander, Spain.
authors.forename: José L
authors.initials: JL
authors.lastname: Hernández
authors.affiliation: Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avda. Valdecilla s/n, ES-39008 Santander, Spain. Electronic address: miguelaggay@hotmail.com.
authors.forename: Miguel A
authors.initials: MA
authors.lastname: González-Gay
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D025241:Spondylarthritis / Q000150:complications*; D016896:Treatment Outcome; D014605:Uveitis / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; C529000:golimumab
keywords: Anti-TNF-α therapy; Golimumab; Refractory; Spondyloarthritis; Uveitis